JP2022542396A5 - - Google Patents
Info
- Publication number
- JP2022542396A5 JP2022542396A5 JP2022506169A JP2022506169A JP2022542396A5 JP 2022542396 A5 JP2022542396 A5 JP 2022542396A5 JP 2022506169 A JP2022506169 A JP 2022506169A JP 2022506169 A JP2022506169 A JP 2022506169A JP 2022542396 A5 JP2022542396 A5 JP 2022542396A5
- Authority
- JP
- Japan
- Prior art keywords
- carboxamide
- imidazole
- alkyl
- pyrimidine
- cyclohexyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025127017A JP2025160384A (ja) | 2019-07-31 | 2025-07-30 | Cd38の阻害剤としてのヘテロ二環式アミド |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880923P | 2019-07-31 | 2019-07-31 | |
| US62/880,923 | 2019-07-31 | ||
| US201962951604P | 2019-12-20 | 2019-12-20 | |
| US62/951,604 | 2019-12-20 | ||
| US202063034750P | 2020-06-04 | 2020-06-04 | |
| US63/034,750 | 2020-06-04 | ||
| PCT/US2020/044156 WO2021021986A1 (en) | 2019-07-31 | 2020-07-30 | Heterobicyclic amides as inhibitors of cd38 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025127017A Division JP2025160384A (ja) | 2019-07-31 | 2025-07-30 | Cd38の阻害剤としてのヘテロ二環式アミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542396A JP2022542396A (ja) | 2022-10-03 |
| JP2022542396A5 true JP2022542396A5 (cg-RX-API-DMAC7.html) | 2023-08-07 |
| JP7721501B2 JP7721501B2 (ja) | 2025-08-12 |
Family
ID=72139677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506169A Active JP7721501B2 (ja) | 2019-07-31 | 2020-07-30 | Cd38の阻害剤としてのヘテロ二環式アミド |
| JP2025127017A Pending JP2025160384A (ja) | 2019-07-31 | 2025-07-30 | Cd38の阻害剤としてのヘテロ二環式アミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025127017A Pending JP2025160384A (ja) | 2019-07-31 | 2025-07-30 | Cd38の阻害剤としてのヘテロ二環式アミド |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11535621B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4003980A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7721501B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220061958A (cg-RX-API-DMAC7.html) |
| CN (2) | CN119431323A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020321956A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022001291A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3147902A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL324885A (cg-RX-API-DMAC7.html) |
| MX (3) | MX2022001019A (cg-RX-API-DMAC7.html) |
| TW (2) | TW202615430A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021021986A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11535621B2 (en) | 2019-07-31 | 2022-12-27 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of CD38 |
| US20230025807A1 (en) * | 2019-10-30 | 2023-01-26 | Mitobridge Inc. | Cd38 inhibitors |
| IL301991A (en) * | 2020-10-09 | 2023-06-01 | Napa Therapeutics Ltd | Heteroaryl amide inhibitors for CD38 |
| AR124718A1 (es) | 2021-01-29 | 2023-04-26 | Ribon Therapeutics Inc | Quinolinas y azaquinolinas como inhibidores de cd38 |
| CN117715897A (zh) * | 2021-04-30 | 2024-03-15 | 南京艾美斐生物医药科技有限公司 | 化合物及其作为cd38抑制剂的用途 |
| US20230116972A1 (en) * | 2021-07-12 | 2023-04-20 | Cytokinetics, Inc. | Cd38 modulators and methods of use thereof |
| CN116041344B (zh) * | 2021-10-28 | 2026-07-24 | 北京望实智慧科技有限公司 | 双环杂芳基甲酰胺化合物作为sos1抑制剂 |
| WO2023084206A1 (en) | 2021-11-09 | 2023-05-19 | Cerevance Ltd | N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors |
| CN114306366B (zh) * | 2021-11-30 | 2023-01-06 | 合肥康诺生物制药有限公司 | 含nad和cd38抑制剂的药物组合物及其用途 |
| WO2023098699A1 (en) * | 2021-12-01 | 2023-06-08 | Nanjing Immunophage Biotech Co., Ltd | Compounds and their uses as cd38 inhibitors |
| GB202207721D0 (en) * | 2022-05-25 | 2022-07-06 | Cerevance Ltd | Novel Compounds |
| EP4567035A4 (en) * | 2022-08-05 | 2026-07-08 | Nextgen Bioscience Co Ltd | NEW COMPOUND USED AS A HYPOXIA-INDUCIBLE FACTOR 1 (HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING IT |
| CN115825297B (zh) * | 2022-11-11 | 2025-03-28 | 武汉海特生物创新医药研究有限公司 | 一种(s)-3-氨基哌啶-2,6-二酮盐酸盐对映异构体的检测方法 |
| EP4713323A1 (en) * | 2023-05-18 | 2026-03-25 | Cerevance, Inc. | 3-carbonyl imidazo[1,5-a]pyridine derivatives for use as cd38 inhibitors for the treatment of cns disorders |
| GB202307426D0 (en) * | 2023-05-18 | 2023-07-05 | Cerevance Inc | Novel compounds |
| EP4724430A1 (en) * | 2023-06-07 | 2026-04-15 | Flagship Pioneering Innovations VI, LLC | Condensed azines as inhibitors of cyclic adp ribose hydrolase |
| WO2026000074A1 (en) * | 2024-06-25 | 2026-01-02 | Welnx Company Inc. | Use of cd38 inhibitors for reducing th2 inflammation |
| WO2026075971A1 (en) | 2024-10-01 | 2026-04-09 | Neolaia Inc. | Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors |
| WO2026090857A1 (zh) * | 2024-10-29 | 2026-05-07 | 甫康(上海)健康科技有限责任公司 | 一种多取代的氨基喹啉类化合物及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2474582C2 (ru) * | 2006-10-19 | 2013-02-10 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы |
| JP5794922B2 (ja) | 2009-12-28 | 2015-10-14 | 一般社団法人ファルマバレープロジェクト支援機構 | 1,3,4−オキサジアゾール−2−カルボキサミド化合物 |
| WO2012005805A1 (en) | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
| EP2646020B1 (en) * | 2010-12-01 | 2016-09-21 | Glaxosmithkline LLC | Indoles |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9073924B2 (en) | 2011-09-13 | 2015-07-07 | Glaxosmithkline Llc | Azaindazoles |
| CN103998036B (zh) * | 2011-10-19 | 2017-05-31 | 西格诺药品有限公司 | 利用tor激酶抑制剂治疗癌症 |
| AU2012332297B2 (en) * | 2011-11-04 | 2016-01-07 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment |
| WO2013067302A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| CN104271159B (zh) * | 2012-02-24 | 2017-11-28 | 西格诺药品有限公司 | 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法 |
| US20150164910A1 (en) | 2012-06-15 | 2015-06-18 | The Regents Of The University Of Califonia | Antiviral compounds and methods of use |
| WO2014037340A1 (de) | 2012-09-05 | 2014-03-13 | Bayer Cropscience Ag | Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress |
| EA201591746A1 (ru) | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
| CN105017221B (zh) | 2014-04-30 | 2019-05-28 | 中国医学科学院药物研究所 | 苯并咪唑衍生物及其制法和药物组合物与用途 |
| CN107428733A (zh) * | 2014-12-03 | 2017-12-01 | 葛兰素史克知识产权第二有限公司 | Cd38抑制剂和治疗方法 |
| WO2017053604A1 (en) | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Potent antiviral pyrazolopyridine compounds |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| EP3434692A1 (en) | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| US11180498B2 (en) * | 2017-09-27 | 2021-11-23 | The Regents Of The University Of California | Substituted pyrrolo[2,3-b]pyridines, pyrazolo[3,4-d]pyrimidines and [1,2,3]triazolo[4,5-b]pyridines as potent antivirals |
| US11535621B2 (en) | 2019-07-31 | 2022-12-27 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of CD38 |
| US20230025807A1 (en) | 2019-10-30 | 2023-01-26 | Mitobridge Inc. | Cd38 inhibitors |
| KR20230051425A (ko) | 2020-04-07 | 2023-04-18 | 미토브리지, 인크. | Cd38 억제제 |
| AR124718A1 (es) | 2021-01-29 | 2023-04-26 | Ribon Therapeutics Inc | Quinolinas y azaquinolinas como inhibidores de cd38 |
-
2020
- 2020-07-30 US US16/942,857 patent/US11535621B2/en active Active
- 2020-07-30 TW TW114124360A patent/TW202615430A/zh unknown
- 2020-07-30 IL IL324885A patent/IL324885A/en unknown
- 2020-07-30 IL IL289878A patent/IL289878B2/en unknown
- 2020-07-30 KR KR1020227006571A patent/KR20220061958A/ko active Pending
- 2020-07-30 TW TW109125742A patent/TWI891649B/zh active
- 2020-07-30 CN CN202411191364.2A patent/CN119431323A/zh active Pending
- 2020-07-30 AU AU2020321956A patent/AU2020321956A1/en not_active Abandoned
- 2020-07-30 CA CA3147902A patent/CA3147902A1/en active Pending
- 2020-07-30 MX MX2022001019A patent/MX2022001019A/es unknown
- 2020-07-30 BR BR112022001291A patent/BR112022001291A2/pt unknown
- 2020-07-30 CN CN202080066542.2A patent/CN114423753B/zh active Active
- 2020-07-30 WO PCT/US2020/044156 patent/WO2021021986A1/en not_active Ceased
- 2020-07-30 JP JP2022506169A patent/JP7721501B2/ja active Active
- 2020-07-30 EP EP20757729.7A patent/EP4003980A1/en active Pending
-
2022
- 2022-01-25 MX MX2025003444A patent/MX2025003444A/es unknown
- 2022-01-25 MX MX2025003445A patent/MX2025003445A/es unknown
- 2022-12-05 US US18/074,746 patent/US11987584B2/en active Active
-
2024
- 2024-04-18 US US18/638,989 patent/US12398146B2/en active Active
-
2025
- 2025-07-15 US US19/269,389 patent/US20260078127A1/en active Pending
- 2025-07-30 JP JP2025127017A patent/JP2025160384A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11931363B2 (en) | Triazolopyrimidine compounds and uses thereof | |
| ES2648143T3 (es) | Derivados de 5,6-dihidro-imidazo[1,2-a]pirazin-8-ilamina útiles como inhibidores de la beta-secretasa (BACE) | |
| ES2638850T3 (es) | Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos | |
| JP7860103B2 (ja) | 複素環式スピロ化合物及びその使用方法 | |
| ES2543216T3 (es) | Moduladores de tiazolopirimidina como agentes inmunosupresores | |
| SI3106463T1 (en) | Substituted pyrazolo(1,5-)pyrimidine compounds as trk kinase inhibitors | |
| RU2011116230A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| ES2733502T3 (es) | Compuestos de imidazopiridazina | |
| TW201619159A (zh) | 吡咯并[2,3-d]嘧啶衍生物 | |
| JP2009529047A5 (cg-RX-API-DMAC7.html) | ||
| JP2023517680A5 (cg-RX-API-DMAC7.html) | ||
| JP2014531449A5 (cg-RX-API-DMAC7.html) | ||
| JP6695353B2 (ja) | Fgfr4阻害剤としてのホルミル化n−複素環式誘導体 | |
| WO2004100868A2 (en) | Method of treating transplant rejection | |
| RU2011116447A (ru) | Модуляторы амилоида бета | |
| JP2009519979A5 (cg-RX-API-DMAC7.html) | ||
| BR112012000413B1 (pt) | Compostos para tratamento de doenças parasitárias, seus usos, e composição | |
| RU2014126750A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
| JP2023539985A5 (cg-RX-API-DMAC7.html) | ||
| RU2018141084A (ru) | Соединения тетрагидропиримидодиазепина и дигидропиридодиазепина для лечения боли и связанных с болью состояний | |
| RU2014109748A (ru) | Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor | |
| JP6392352B2 (ja) | リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての[1,2,4]トリアゾロ[1,5−a]ピリミジン誘導体 | |
| ES2775674T3 (es) | Compuestos de 6,7-dihidro-5H-pirazolo[5,1-b][1,3]oxazina-2-carboxamida | |
| JP2022539208A (ja) | チロシンキナーゼ非受容体1(tnk1)阻害剤およびその使用 |